Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol (original) (raw)

Authors/Creators:

• Al-Laith, M
• Jasenecova, M
• Abraham, S
• Bosworth, A
• Bruce, IN
• Buckley, CD
• Ciurtin, C
• D'Agostino, M-A
• Emery, P https://orcid.org/0000-0002-7429-8482
• Gaston, H
• Isaacs, JD
• Filer, A
• Fisher, BA
• Huizinga, TWJ
• Ho, P
• Jacklin, C
• Lempp, H
• McInnes, IB
• Pratt, AG
• Östor, A
• Raza, K
• Taylor, PC
• van Schaardenburg, D
• Shivapatham, D
• Wright, AJ
• Vasconcelos, JC
• Kelly, J
• Murphy, C
• Prevost, AT
• Cope, AP

Copyright, Publisher and Additional Information:

(c) 2019, the Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Keywords:

Rheumatoid arthritis, At risk, Pre-clinical phase, Intervention, Abatacept, Double-blind, Antibodies to citrullinated protein antigens, Autoantibodies, Placebo-controlled, Randomised